Review of the efficacy and safety of antidepressants in youth depression

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 46, Issue 7, 2005, Pages 735-754

  Cheung, Amy H ^a,c   Emslie, Graham J ^b   Mayes, Taryn L ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE   (Canada)

Author keywords

Adolescents; Antidepressants; Children; Clinical trials; Efficacy; Review; Safety

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; AGITATION; AKATHISIA; ALOPECIA; ANALYSIS OF VARIANCE; ANXIETY; APPENDICITIS; AUTOMUTILATION; CALCULATION; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEADACHE; HUMAN; HYPOMANIA; INFORMATION PROCESSING; INSOMNIA; IRRITABILITY; KIDNEY INFECTION; MANIA; MENTAL INSTABILITY; METHODOLOGY; PANIC; PSYCHOPHARMACOTHERAPY; PUBLICATION; RASH; REVIEW; RISK BENEFIT ANALYSIS; SUICIDE ATTEMPT; TONSILLITIS; VIRUS INFECTION;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; CHILD; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RISK; SAFETY; SEROTONIN UPTAKE INHIBITORS; SUICIDE; TREATMENT OUTCOME;

EID: 21644470916     PISSN: 00219630     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-7610.2005.01467.x     Document Type: Review

References (32)

1. Brent, D.A., Kolko, D.J., Birmaher, B., Baugher, M., Bridge, J., Roth, C., & Holder, D. (1998). Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 906-914.
2. American Psychiatric Press. (1994). Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington, DC: American Psychiatric Press.
3. Emslie, G.J., Heiligenstein, J.H., Wagner, K.D., Hoog, S.L., Ernest, D.E., Brown, E., Neilsson, M., & Jacobson, J.G. (2002a). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
4. Emslie, G.J., Findling, R.L., Rynn, M.A., Marcus, R.N., Fernandes, L.A., D'Amico, M.F., & Hardy, S.A. (2002b). Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology, 12, 299.
5. Emslie, G.J., Findling, R.L., Yeung, P.P., Kunz, N.R., Li, Y., & Durn, B.L. (2004a). Efficacy and safety of venlafaxine ER in children and adolescents with major depressive disorder. Presented at the American Psychiatric Association, New York, May.
6. Emslie, G.J., Wagner, K.D., Kutcher, S.P., Krulewicz, S., Carpenter, D.J., & Lipschitz, A. (2004b). Paroxetine treatment in children and adolescents with major depression disorder. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC.
7. Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Hughes, C.W., Carmody, T., & Rintelmann, J.W. (1997). Double-blind placebo controlled study of fluoxetine in depressed children and adolescents. Archives of General Psychiatry, 54, 1031-1037.
8. Emslie, G.J., Weinberg, W.A., Rush, A.J., Adams, R.M., & Rintelmann, J.W. (1990). Depressive symptoms by self-report in adolescence. Journal of Child Neurology, 3, 114-121.
9. Greenhill, L., Vitiello, B., Riddle, M., et al. (2003). Review of safety assessment methods used in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 627-633.
10. Harrington, R., Fudge, H., Rutter, M., Pickles, A., & Hill, J. (1990). Adult outcomes of childhood and adolescent depression. I: Psychiatric status. Archives of General Psychiatry, 47, 465-473.
11. Hazell, P., O'Connell, D., Heathcote, D., & Henry, D. (2002). Tricyclic drugs for depression in children and adolescents. Cochrane Database Systems Review, 2, CD002317.
12. Jaffee, S.R., Moffitt, R.E., Caspi, A., Fombonne, E., Poulton, R., & Martin, J. (2002). Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Archives of General Psychiatry, 59, 215-222.
13. Jensen, P., Bhatara, V., Vitiello, B., Hoagwood, K., Feil, M., & Burke, L.B. (1999). Psychoactive medication prescribing practices for US children: Gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 557-565.
14. Jensen, P.S., Ryan, N.D., & Prien, R. (1992). Psychopharmacology of child and adolescent major depression. Journal of Child Psychopharmacology, 2, 31-45.
15. Keller, M.B., Ryan, N.D., Strober, M., Klein, R.G., Kutcher, S.P., Birmaher, B., Hagino, W.R., Koplewicz, H., Carlson, G.A., Clarke, G.N., Emslie, G.J., Feinberg, D., Geller, B., Kusumakar, V., Paptheodorou, G., Sack, W.H., Sweeney, M., Wagner, K.D., Weller, E.B., Winters, N.C., Oakes, R., & McCafferty, J.P. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 762-772.
16. Mandoki, M.W., Tapia, M.R., Tapia, M.A., Sumner, G.S., & Parker, J.L. (1997). Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacological Bulletin, 33, 149-154.
17. March, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., Burns, B., Domino, M., McNulty, S., Vitiello, B., & Severe, J. (2004). Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 292, 807-820.
18. Martin, A., Young, C., Leckman, J.F., Mukonoweshuro, C., Rosentheck, R., & Leslie, D. (2004). Age effects on antidepressant-induced manic conversion. Archives of Pediatric Adolescent Medicine, 158, 773-780.
19. MMWR. (2002). Youth risk behavior surveillance. CDC, 51, ss-4.
20. National Center for Health Statistics. (2001). Death rates for 72 selected causes, by 5-year groups, race and sex: United States, 1979-1997. Hyattsville, MD: National Center for Health Statistics, 485-490.
21. Olfson, M., Shaffer, D., Marcus, S.C., & Greenberg, T. (2003). Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry, 60, 978-982.
22. Poznanski E.O.,Grossman J.A., Buchsbaum Y., Banegas M. ,Freeman L., & Gibbons R. (1984). Preliminary studies of the reliability and validity of the children's depression rating scale. Journal of the American Academy of Child and Adolescent Psychiatry, 23, 191-197.
23. Rabkin, J.G., & Markowitz, J.S. (1986). Side effect assessment with SAFTEE. Psychopharmacological Bulletin, 22, 389-396.
24. Rintelmann, J.W., Emslie, G.J., Rush, A.J., Varghese, T., Gullion, C.M., Kowatch, R.A. & Hughes, C.W. (1996). The effects of extended evaluation on depressive symptoms in children and adolescents. Journal of Affective Disorders, 41, 149-156.
25. Shaffer, D., & Waslick, B. (2002). The many faces of depression. Washington, DC: American Psychiatric Publishing.
26. Simeon, J.G., Dinicola, V.F., Ferguson, B.H., & Copping, W. (1990). Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 14, 791-795.
27. Wagner, K.D., Ambrosini, P.J., Rynn, M., et al. (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. Journal of the American Medical Association, 290, 1033-1041.
28. Wagner, K.D., Robb, A.S., Findling, R.L., Jin, J., Gutierrez, M.M., & Heydorn, W.E. (2004). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry, 161, 1079-1083.
29. Weissman, M.M., Wolk, S., Goldstein, R.B., Moreau, D., Adams, P., Greenwald, S., Klier, C.M., Ryan, N.D., Dahl, R.E., & Wickramaratne, P. (1999). Depressed adolescents grown up. Journal of the American Medical Association, 281, 1707-1713.
30. FDA website: http://www.fda.gov/cder/drug/antidepressants/
31. MHRA website: http://www.mhra.gov.uk/news/2003.htm
32. GSK website: GlaxoSmith Kline website: http://www.gsk.com/media/paroxetine.htm